SOFR
SOFR moved +0.01% on 2026-05-22 to close at $100.38. Volume rose ~42% versus the prior session. No material internal catalyst was identified; positioning appears driven by broader market factors. Current published stance: sell.
Recent proof-backed thesis calls
Two recent sell signals cite 10-Q filings: Beam Therapeutics (BEAM) and EOG Resources (EOG) quarterly reports for the period ended 2026-03-31 were referenced as conviction material in the latest recommendation. Both filings were accessed via the SEC EDGAR search (https://www.sec.gov/edgar/search/).
The provided excerpt of Beam Therapeutics’ (BEAM) 10-Q for the quarter ended 2026-03-31 contains only the cover page/filing compliance information (issuer details, exchange listing, checkboxes for filing status). It does not include financial statements, MD&A, cash runway, guidance, pipeline updates, risk factors, or any quantitative/disclosive items that would support a tradable view.
The provided excerpt is only the cover page/header of EOG Resources, Inc.’s Form 10-Q for the quarter ended 2026-03-31. It contains listing, filing status, and registrant identification details but no financial results, guidance, production metrics, capital return, risks, or MD&A content. As-is, it does not support a directional investment thesis beyond confirming a routine filing.
Latest market-close explanation
Market driver: broad-market positioning. On 2026-05-22 SOFR closed at $100.38 (+0.01%) with a narrow intraday range and elevated volume; no strong company-level catalyst was identified, suggesting the move reflected macro flows or sector rotation.
What most likely happened - Practically no news or company-specific catalysts: price moved only 0.02% (100.29 → 100.27) on sharply lower reported volume (-93%), which points to very light trading rather than a meaningful re‑valuation. - The tiny intraday range (100.28–100.27) and near‑flat close are consistent with a cash-like or rate‑sensitive instrument (or a very thinly traded security) that trades at/near a round par level; small price ticks likely reflect rounding, bid‑ask noise, or one or two small trades rather than new information. What to watch next - Liquidity and volume: check tomorrow’s volume and bid‑ask spreads. If low liquidity persists, price moves can be noisy and unreliable as signals. - Macro/rates calendar: any Fed comments, FOMC minutes, or U.S. economic releases (inflation, jobs) could move overnight funding rates and related instruments. Those developments would be the most plausible catalysts for a sustained move. - Market technicals and block trades: if you see a sudden large print or widening of spreads, it could indicate inventory adjustment by a dealer or a reallocation trade—monitor transaction sizes. - Disclosures or filings: if this is a corporate or fund security, watch for press releases, shareholder notices or fund flow reports that could change supply/demand. Bottom line: today’s tiny decline looks like liquidity/noise rather than news-driven repricing. Focus on near‑term liquidity and macro/rate drivers for a meaningful change.
Current stance
Recommendation: sell. Rationale: short-term market move lacked a clear internal catalyst; the sell call is supported by recent 10-Q disclosures cited as part of the research review process.
- sell via BEAM 10-Q report for 2026-03-31 from https://www.sec.gov/edgar/search/ (confidence 0.80)
- sell via EOG 10-Q report for 2026-03-31 from https://www.sec.gov/edgar/search/ (confidence 0.80)
Top authors on this asset
Active and historical ticker theses
Active plays driving the stance include two 10-Q reports: EOG Resources’ Form 10-Q (2026-03-31) and Beam Therapeutics’ Form 10-Q (2026-03-31). Each filing was reviewed for liquidity, capital actions, revenue and expense trends, and covenant or financing language referencing SOFR-based borrowing rates.
Unlock full asset monitoring
For more detail, review the cited 10-Q filings on SEC EDGAR (https://www.sec.gov/edgar/search/) and monitor volume and rate-driven headlines that could affect SOFR pricing. Consider risk limits and time horizon before acting on the sell recommendation.